BCLSI
Bain Capital Life Sciences Investors Portfolio holdings
AUM $799M
1-Year Return
36.47%
This Quarter Return
+170.14%
1 Year Return
+36.47%
3 Year Return
+278.05%
5 Year Return
+363.53%
10 Year Return
–
AUM
$671M
AUM Growth
+$282M
(+73%)
Cap. Flow
+$104M
Cap. Flow
% of AUM
15.51%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
3
Increased
1
Reduced
1
Closed
–
Top Buys
| 1 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$133M |
| 2 |
Savara
SVRA
|
+$23M |
| 3 |
X4 Pharmaceuticals
XFOR
|
+$17.6M |
| 4 |
MRNS
Marinus Pharmaceuticals, Inc
MRNS
|
+$1.94M |
Top Sells
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$71.6M |
Sector Composition
| 1 | Healthcare | 84.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
| $280M | 41.8% |
7,281,307
| – | – |
|
|
CNST
2
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $133M | 19.84% |
+2,823,529
| New | +$133M |
|
|
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $89.9M | 13.41% |
4,080,237
-3,250,000
| -44% | -$71.6M |
|
4
Dynavax Technologies
DVAX
$1.14B
| $48.3M | 7.21% |
8,452,235
| – | – |
|
5
Replimune Group
REPL
$443M
| $40.7M | 6.08% |
2,838,968
| – | – |
|
|
6
Savara
SVRA
$624M
| $23M | 3.43% |
+5,128,593
| New | +$23M |
|
|
7
X4 Pharmaceuticals
XFOR
$72.1M
| $17.6M | 2.63% |
+54,950
| New | +$17.6M |
|
8
Solid Biosciences
SLDB
$421M
| $17.2M | 2.57% |
258,078
| – | – |
|
|
MRNS
9
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $12.8M | 1.91% |
1,485,684
+225,000
| +18% | +$1.94M |
|
|
APTX
10
DELISTED
Aptinyx Inc. Common Stock
APTX
| $7.61M | 1.13% |
2,225,092
| – | – |
|